A Long-Term Study of Aripiprazole in Patients With Major Depressive Disorder
NCT ID: NCT00095745
Last Updated: 2013-11-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
1002 participants
INTERVENTIONAL
2004-09-30
2007-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Antidepressant + Aripiprazole
Antidepressant + Aripiprazole
Antidepressant Caps/Tablets Aripiprazole Tablets, Oral, 2-30mg Aripiprazole, once daily, 52-weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Antidepressant + Aripiprazole
Antidepressant Caps/Tablets Aripiprazole Tablets, Oral, 2-30mg Aripiprazole, once daily, 52-weeks.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Experiencing Major Depressive Disorder with a duration of minimally 8 weeks.
* Treatment history of an inadequate response to at least one and no more than four antidepressants
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Otsuka America Pharmaceutical
INDUSTRY
Otsuka Pharmaceutical Development & Commercialization, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bristol-Myers Squibb
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution
Mesa, Arizona, United States
Local Institution
Peoria, Arizona, United States
Local Institution
Beverly Hills, California, United States
Local Institution
Burbank, California, United States
Local Institution
Encino, California, United States
Local Institution
Garden Grove, California, United States
Local Institution
National City, California, United States
Local Institution
Orange, California, United States
Local Institution
Pasadena, California, United States
Local Institution
Riverside, California, United States
Local Institution
San Diego, California, United States
Local Institution
Denver, Colorado, United States
Local Institution
Farmington, Connecticut, United States
Local Institution
Washington D.C., District of Columbia, United States
Local Institution
Gainesville, Florida, United States
Local Institution
Jacksonville, Florida, United States
Local Institution
Orlando, Florida, United States
Local Institution
Atlanta, Georgia, United States
Local Institution
Smyrna, Georgia, United States
Local Institution
Chicago, Illinois, United States
Local Institution
Edwardsville, Illinois, United States
Local Institution
Oakbrook Terrace, Illinois, United States
Local Institution
Terre Haute, Indiana, United States
Local Institution
Overland Park, Kansas, United States
Local Institution
Wichita, Kansas, United States
Local Institution
Lexington, Kentucky, United States
Local Institution
Rockville, Maryland, United States
Local Institution
Springfield, Massachusetts, United States
Local Institution
Farmington Hills, Michigan, United States
Local Institution
Okemos, Michigan, United States
Local Institution
Albuquerque, New Mexico, United States
Local Institution
Brooklyn, New York, United States
Local Institution
New York, New York, United States
Local Institution
Staten Island, New York, United States
Local Institution
Chapel Hill, North Carolina, United States
Local Institution
Raleigh, North Carolina, United States
Local Institution
Cincinnati, Ohio, United States
Local Institution
Toledo, Ohio, United States
Local Institution
Portland, Oregon, United States
Local Institution
Philadelphia, Pennsylvania, United States
Local Institution
Pittsburgh, Pennsylvania, United States
Local Institution
East Providence, Rhode Island, United States
Local Institution
Charleston, South Carolina, United States
Local Institution
Memphis, Tennessee, United States
Local Institution
Austin, Texas, United States
Local Institution
Dallas, Texas, United States
Local Institution
Houston, Texas, United States
Local Institution
Salt Lake City, Utah, United States
Local Institution
Woodstock, Vermont, United States
Local Institution
Arlington, Virginia, United States
Local Institution
Charlottesville, Virginia, United States
Local Institution
Herndon, Virginia, United States
Local Institution
Richmond, Virginia, United States
Local Institution
Bellevue, Washington, United States
Local Institution
Seattle, Washington, United States
Local Institution
Morgantown, West Virginia, United States
Local Institution
Brown Deer, Wisconsin, United States
Local Institution
Middleton, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Clayton AH, Baker RA, Sheehan JJ, Cain ZJ, Forbes RA, Marler SV, Marcus R, Berman RM, Thase ME. Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study. BMC Res Notes. 2014 Jul 18;7:459. doi: 10.1186/1756-0500-7-459.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CN138-164
Identifier Type: -
Identifier Source: org_study_id